Human African trypanosomiasis of the CNS: current issues and challenges.

Human African trypanosomiasis (HAT), also known as sleeping sickness, is a major cause of mortality and morbidity in sub-Saharan Africa. Current therapy with melarsoprol for CNS HAT has unacceptable side-effects with an overall mortality of 5%. This review discusses the issues of diagnosis and staging of CNS disease, its neuropathogenesis, and the possibility of new therapies for treating late-stage disease.

[1]  T. Niyonsenga,et al.  Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[2]  F. Kuzoe.  Current situation of African trypanosomiasis. , 1993, Acta tropica.

[3]  G. H. Coombs,et al.  Landmarks in trypanosome research. , 1997 .

[4]  J. Baker.  Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. , 1999, World Health Organization technical report series.

[5]  V. Jamonneau,et al.  Comparison of different DNA preparation protocols for PCR diagnosis of Human African Trypanosomosis in Côte d'Ivoire. , 2002, Acta tropica.

[6]  J. Burke,et al.  A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. P. Hutchinson,et al.  Sleeping sickness in Europeans: a review of 109 cases. , 1966, The Journal of tropical medicine and hygiene.

[8]  J. Rodgers,et al.  Vitamin B12 deficiency , 2002, The Lancet.

[9]  A. Fairlamb,et al.  Trypanothione is the primary target for arsenical drugs against African trypanosomes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Rodgers,et al.  Sleeping sickness: new drugs from old? [corrected]. , 2002, Lancet.

[11]  V. Pentreath.  Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London, 19 May 1994. Trypanosomiasis and the nervous system. Pathology and immunology. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  Terry K. Smith,et al.  Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial , 2000, The Lancet.

[13]  R. Docampo,et al.  A calmodulin-stimulated Ca2+ pump in plasma-membrane vesicles from Trypanosoma brucei; selective inhibition by pentamidine. , 1993, The Biochemical journal.

[14]  H. Méda,et al.  The epidemiology and control of human African trypanosomiasis. , 2001, Advances in parasitology.

[15]  C. Burri,et al.  Eflornithine for the treatment of human African trypanosomiasis , 2003, Parasitology Research.

[16]  D. Chatha,et al.  MR imaging findings in African trypansomiasis. , 2003, AJNR. American journal of neuroradiology.

[17]  S. Hunt,et al.  Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. , 2003, Brain : a journal of neurology.

[18]  P. Kennedy,et al.  Neurological aspects of human African trypanosomiasis , 2000 .

[19]  M. Bakhiet,et al.  Chemokines are produced in the brain early during the course of experimental African trypanosomiasis , 2000, Journal of Neuroimmunology.

[20]  Duggan Aj,et al.  Sleeping sickness in Europeans: a review of 109 cases. , 1966 .

[21]  J. Sternberg.  Immunobiology of African trypanosomiasis. , 1998, Chemical immunology.

[22]  F. Milord,et al.  The treatment of human African trypanosomiasis. , 1994, Advances in parasitology.

[23]  P. Kennedy,et al.  Astrocyte activation correlates with cytokine production in central nervous system of Trypanosoma brucei brucei-infected mice. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[24]  C. Burri,et al.  Treatment of human African trypanosomiasis--present situation and needs for research and development. , 2002, The Lancet. Infectious diseases.

[25]  T. Mak,et al.  CD8 is critically involved in lymphocyte activation by a T. brucei brucei-released molecule , 1993, Cell.

[26]  B. Metcalf,et al.  Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by substrate and product analogs , 1978 .

[27]  H. Filutowicz,et al.  Characterization of T helper cell responses to the trypanosome variant surface glycoprotein. , 1993, Journal of immunology.

[28]  G. H. Coombs,et al.  The biology of antigenic variation in African trypanosomes. , 1997 .

[29]  V. Jamonneau,et al.  IgM quantification in the cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test , 2002, Tropical medicine & international health : TM & IH.

[30]  M. Ferguson,et al.  The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. , 1998, Journal of immunology.

[31]  D. Paulnock,et al.  Analysis of macrophage activation in African trypanosomiasis , 2001, Journal of leukocyte biology.

[32]  K. Kristensson,et al.  From trypanosomes to the nervous system, from molecules to behavior: A survey, on the occasion of the 90th anniversary of Castellani's discovery of the parasites in sleeping sickness , 1994, The Italian Journal of Neurological Sciences.

[33]  J. Adams,et al.  Subcurative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis , 1992, The Lancet.

[34]  P. Kennedy,et al.  Immunopathology in central nervous system human African trypanosomiasis , 1992, Journal of Neuroimmunology.

[35]  J. Adams,et al.  HUMAN AFRICAN TRYPANOSOMIASIS (T.b. GAMBIENSE): A STUDY OF 16 FATAL CASES OF SLEEPING SICKNESS WITH SOME OBSERVATIONS ON ACUTE REACTIVE ARSENICAL ENCEPHALOPATHY , 1986, Neuropathology and applied neurobiology.

[36]  J. Donelson,et al.  The Gene for a T Lymphocyte Triggering Factor from African Trypanosomes , 1997, The Journal of experimental medicine.

[37]  A. Fairlamb.  Future prospects for the chemotherapy of human trypanosomiasis. 1. Novel approaches to the chemotherapy of trypanosomiasis. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[38]  P. Lambert,et al.  Immune complexes in serum and in cerebrospinal fluid in African trypanosomiasis. Correlation with polyclonal B cell activation and with intracerebral immunoglobulin synthesis. , 1981, The Journal of clinical investigation.

[39]  A. Fairlamb,et al.  "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Kennedy.  The pathogenesis and modulation of the post-treatment reactive encephalopathy in a mouse model of Human African Trypanosomiasis , 1999, Journal of Neuroimmunology.

[41]  K. Kristensson,et al.  Trypanosoma brucei and the nervous system , 1994, Trends in Neurosciences.

[42]  Hugh Waddell Mulligan,et al.  The African trypanosomiases , 1970 .

[43]  G. Strassmann,et al.  Suramin inhibits the stimulation of acute phase plasma protein genes by IL-6-type cytokines in rat hepatoma cells. , 1993, Journal of immunology.

[44]  I. Löwy.  The Wellcome Trust illustrated history of tropical diseases , 1997, Medical History.

[45]  J. Pépin,et al.  TRIAL OF PREDNISOLONE FOR PREVENTION OF MELARSOPROL-INDUCED ENCEPHALOPATHY IN GAMBIENSE SLEEPING SICKNESS , 1989, The Lancet.

[46]  A. Poltera.  Immunopathological and chemotherapeutic studies in experimental trypanosomiasis with special reference to the heart and brain. , 1980, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[47]  J. Sternberg,et al.  Nitric oxide and cytokine synthesis in human African trypanosomiasis. , 2001, The Journal of infectious diseases.

[48]  D. Legros,et al.  Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[49]  V. Jamonneau,et al.  Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire , 2003, Tropical medicine & international health : TM & IH.

[50]  S. Aksoy.  Control of tsetse flies and trypanosomes using molecular genetics. , 2003, Veterinary parasitology.

[51]  J. Gow,et al.  Immunopathology of experimental African sleeping sickness: detection of cytokine mRNA in the brains of Trypanosoma brucei brucei-infected mice , 1991, Infection and immunity.

[52]  E. Bosmans,et al.  Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[53]  V. Pentreath.  Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London, 19 May 1994. Trypanosomiasis and the nervous system. Pathology and immunology. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[54]  V. Jamonneau,et al.  Evaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and LATEX/T b gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central Africa. , 2002, Bulletin of the World Health Organization.

[55]  H. Reiber,et al.  Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. , 2003, The Journal of infectious diseases.

[56]  P. Kennedy,et al.  The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis , 1997, Neuropathology and applied neurobiology.

[57]  J. Pépin,et al.  African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis. , 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[58]  V. Pentreath.  Neurobiology of sleeping sickness. , 1989, Parasitology today.

[59]  J. Donelson,et al.  Antigenic variation and the African trypanosome genome. , 2003, Acta tropica.